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 A STUDY OF EFFICACY OF TRANSDERMAL NITROGLYCERINE              
PATCH IN  ENHANCING ANALGESIA OF INTRATHECAL 
NEOSTIGMINE FOLLOWING HYSTERECTOMIES UNDER 
BUPIVACAINE SPINAL ANAESTHESIA 
 
                                                Abstract 
This study was carried out to assess the effect of transdermal nitroglycerine 
patch on intrathecal neostigmine with bupivacaine on postoperative analgesia 
and note the incidence of adverse effects, if any. After taking informed consent, 
76 patients of ASA Grade I and II were systematically randomised into three 
groups of 26 each. Patients were hydrated with Ringer's lactate solution 10ml/kg 
preoperatively. Group C patients received Intrathecal injection of 15 mg 
bupivacaine. Group N patients received Intrathecal injection of 15 mg 
bupivacaine with 25 mcg of neostigmine .Group P patients received Intrathecal 
injection of 15 mg bupivacaine with 5mcg of neostigmine and transdermal 
nitroglycerine patch (5 mg/24 hours), applied on a non anaesthetised area after 
15 minutes. Groups were demographically similar and did not differ in 
intraoperative characteristics like duration of surgery, and hemodynamic 
parameters . The mean duration of analgesia was 150.4 minutes, 211.3 minutes, 
316.3 in control group (C), neostigmine group (N), and nitroglycerine patch- 
neostigmine group (P) respectively (P<0.01). There was no significant changes 
in perioperative hemodynamic parameters, but incidence of nausea and 
vomiting were increased due to addition of intrathecal neostigmine.To 
conclude, our results show that transdermal nitroglycerine enhances the 
analgesic potential of intrathecal neostigmine.  
Keywords: Abdominal hysterectomy, neostigmine, nitroglycerine, nitric oxide, 
postoperative analgesia 
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INTRODUCTION 
            Pain is derived from the Latin word ―poena‖, which means penalty or 
punishment. Pain is no longer considered a penalty or punishment. The relief of 
pain is one of the paramount goals of medical science. 
 Surgery is a severe tissue damage and post-operative pain is a universal 
phenomenon experienced by millions of patients throughout the world, yet 
paradoxically after all the efforts taken to make intraoperative period pain and 
stress free, the patients is left to fend for himself in the postoperative period. 
 Neuraxial blockade is one of the answers to control post-operative pain. 
Neostigmine is the universally used neuromuscular block reversal agent whose 
post-operative pain relief property was first described by Naguib and Yaksh et 
al in 1994. It inhibits the breakdown of acetylcholine (endogenous 
neurotransmitter) which has been shown to cause analgesia by stimulating the 
synthesis of nitric oxide [NO] in the spinal cord. It blocks the activity of both 
true and pseudocholinesterase and thereby enhancing accumulation and binding 
of acetylcholine at various cholinergic sites. 
         But a higher dose of neostigmine shown to produce many untoward side 
effects such as nausea, vomiting etc. and lower doses of neostigmine doesn‘t 
show much analgesic property. So as to reduce dose of neostigmine and 
potentiate its analgesic property other adjuvants like clonidine, opioids, 
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transdermal nitroglycerine patch etc. have been added along with it. 
 The transdermal nitroglycerine acts as a source for  nitric oxide (NO) .NO  
acts as a second messenger in the CNS  and plays an important role in the 
mediation of pain. Intracellular cGMP levels are increased by NO by activation 
of enzyme guanyl cyclase. This Nitric Oxide-cyclic GMP cascade in endothelial 
cells mediates acetylcholine induced vasodilatation as well as acetylcholine 
induced antinociception. 
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                  AIM OF THE STUDY  
1) To evaluate and compare the efficacy and safety of combining intrathecal         
neostigmine with transdermal nitroglycerine patch for pain relief in 
patients undergoing hysterectomies under bupivacaine spinal anaesthesia. 
  
2) To evaluate the adverse effects of transdermal nitroglycerine patch and 
intrathecally administered neostigmine in patients undergoing 
hysterectomies under bupivacaine spinal anaesthesia. 
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                                   REVIEW OF LITERATURE 
              Cerebrospinal fluid was discovered by Domenico Cotugno in 1764 and 
its circulation was described by F.Magendie in 1825 who also named it. 
 The first neuraxial block was performed 8 months after the 
demonstration in Heidelberg, Germany, of the local anaesthetic properties of 
cocaine in 1884. James Leonard Corning (1855-1923) was a neurologist who 
had learned of the action of cocaine, injected a total of 120 mg of cocaine 
between the T11 and T12 spinous processes in a 45-year-old man and obtained 
loss of sensation of the legs and perineum. 
 Heinrich Iraneus Quincke of Keil in Germany standardized the lumbar 
puncture as a simple procedure in 1891.In the same year Essex Wynter 
described lumbar puncture in England. 
 On 16th of August 1898, in Keil, Germany, August Bier performed the 
first planned spinal anaesthesia in man. He injected 3ml of 0.5% cocaine into 
the subarachnoid space of a 34 year old labourer for operation on the lower 
limb. After using it on 6 patients, he and his assistant injected cocaine into each 
other's spinal spaces. 
            Yaksh TL et al. in 1985 studied the antinociceptive effects of 
intrathecally injected cholinomimetic drugs in rat and cat with carbachol and 
physostigmine. They found potent antinociceptive effects in rats and cats by 
injection of carbachol, acetylcholine and physostigmine. Atropine reversed this 
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antinociceptive effect. This suggests the involvement of muscarinic cholinergic 
mechanism. There was also absence of changes in general reflex motor function 
or postural control. They concluded that muscarinic agonists are effective as 
antinociceptive agents after low dose intrathecal administration.
[1]
 
          Hood DD et al. in 1995 studied the cardiorespiratory and spinal cord 
blood flow effects of intrathecal neostigmine methylsulfate, clonidine and their 
combination in sheep. They concluded that intrathecal neostigmine alone or in 
combination with clonidine does not reduce spinal cord blood flow, an 
important toxicity issue. These results proved additional support for initial 
clinical trials of intrathecal neostigmine for analgesia.[6] 
 
         Lauretti GR et al. in 1996 conducted a study designed to examine post 
operative analgesia with intrathecal neostigmine in a randomized blinded trial 
with morphine as the active control in patients undergoing anterior and posterior 
vaginoplasty. They concluded that spinal neostigmine produces analgesia 
similar in duration to spinal morphine and that the combination of morphine and 
neostigmine may allow a reduction in the dose of each component for post 
operative analgesia.[7] 
 
Lauretti GR et al. in 1996 conducted a double blind study on 27 female 
patients posted for both tubal ligation and vaginoplasty at the same surgical 
time. They concluded that 100μg of intrathecal neostigmine was more effective 
in the treatment of vaginal somatic pain, compared with tubal ligation visceral 
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pain. The addition of a peripheral anticholinergic substantially improved the 
intrathecal neostigmine analgesic effect on visceral pain.[8] 
 
Krukowski JA et al. in 1997 conducted a dose response study of 
intrathecal neostigmine for post caesarean section analgesia and suggested that 
neostigmine is associated with reduced post operative morphine requirement, 
and effect that lasts approximately 10 hours. [10] 
 
Klamt JG et al. in 1997 conducted a study on post operative analgesic 
effect of intrathecal neostigmine. They concluded that in patients undergoing 
anterior and posterior vaginoplasty under spinal anaesthesia, provided analgesia 
lasting for about 12hours. [11] 
 
Lauretti GR et al. 1998 conducted a multicenter study of intrathecal 
neostigmine for analgesia on 92 patients undergoing vaginal hysterectomy under 
spinal anaesthesia with doses of 25μg, 50μg and 75μg of neostigmine and 
concluded that analgesia from intrathecal neostigmine may occur at doses less 
than 50μg. In these doses, neostigmine does not reduce spinal-bupivacaine 
induced hypotension but may increase the need for treatment of nausea. [18] 
          ChoSS et al. in 1998 conducted a study on effect of intrathecal 
neostigmine on post-cesarean section analgesia. This study was designed to 
evaluate the efficacy and safety of intrathecal neostigmine for post-caesarean 
section analgesia. Forty-five women undergoing cesarean section under spinal 
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anaesthesia were randomly assigned into 3 groups to receive normal saline 0.2 
ml, or neostigmine 12.5 microgram, or neostigmine 25 microgram intrathecally 
along with 0.5% hyperbaric bupivacaine 12 mg. Degrees of sensory and motor 
blocks, maternal hemodynamic changes, and side effects were recorded. Apgar 
scores and umbilical vein blood gas analysis (UVBGA) were checked for 
evaluation of fetal status.  There were no significant differences among the three 
groups in characteristics of spinal anaesthesia, maternal blood pressure and heart 
rate, Apgar scores, and UVBGA data. Compared to saline group, intrathecal 
neostigmine significantly prolonged time for first PCA use and decreased 24 hr 
and 48 hr PCA consumptions (P<0.05). Pain scores in neostigmine groups were 
significantly lower than those in saline group for first 4 hours after which there 
were no differences among the three groups. There were significantly higher 
incidence of nausea and vomiting in neostigmine groups than in saline group. 
Their study data indicate that intrathecal neostigmine can be an alternative 
postoperative analgesic without adverse fetal effects for cesarean section. 
However, high incidence of nausea and vomiting seem to limit its clinical 
usefulness.
 [19]
 
              Liu SS et al. in 1999 studied the effects of spinal neostigmine added to 
bupivacaine spinal anaesthesia in volunteers in a varying dose of 6.25μg, 12.5μg 
or 50μg. The addition of 50μg significantly increased the duration of sensory 
and motor blockade, but with higher incidence of side effects such as nausea 
and vomiting and may limit the clinical use of these doses for spinal 
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anaesthesia.
[20 ]
 
 
Dwivedi A et al.  in 2000 did a study on intrathecal neostigmine for post 
operative pain relief and concluded that intrathecal neostigmine significantly 
reduces pain and analgesic requirements in the post operative period, but the 
severity of adverse effects like nausea and vomiting might restrict the usefulness 
of intrathecal neostigmine as sole post operative analgesic.
 [21]  
          Saini S et al. (2006) undertook a study to evaluate the efficacy and safety 
of intrathecal neostigmine in two different doses for the relief of post operative 
pain in patients undergoing elective lower abdominal surgery under spinal 
anaesthesia. The two study groups used intrathecal neostigmine in doses of 50μg 
and 150μg with bupivacaine 12.5mg (0.5%) and compared the results with that 
of control group which used bupivacaine 12.5mg (0.5%) alone. They concluded 
that duration of analgesia (time for requirement of first rescue analgesic) was 
significantly prolonged in 150μg neostigmine group and average 24 hour VAS 
score was lower in both the neostigmine groups. The incidence of vomiting was 
higher in both the neostigmine groups when compared to control group and was 
dose independent
. [23]
 
        Lauretti, Gabriela R. et al. in 2000 conducted a study to determine 
whether association of transdermal nitroglycerine would enhance analgesia from 
a low dose of intrathecal neostigmine in patients undergoing gynaecologic 
surgery during spinal anaesthesia. Their study concluded that neither intrathecal 
5 μg neostigmine alone nor transdermal nitroglycerine alone (5 mg/day) showed 
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analgesic potential but their combination provided an average of 14 hours of 
postoperative analgesia after vaginoplasty. 
[22]
 
             Gurvinder Kaur, Narjeet Osahan, Lalita Afzal in 2007 conducted a 
study to examine the effect of transdermal NTG patch (5mg/24hours) on 
intrathecally administered neostigmine (5μg) and incidence of untoward effects. 
They found that average duration of analgesia in intrathecal neostigmine alone 
group (Group I) was 6.50 hours and in neostigmine with transdermal 
nitroglycerine patch group (Group II) was 9.10 hours. Duration of analgesia was 
significantly higher in Group II patients as compared to Group I. Patients in 
Group II required fewer rescue analgesia in first 24 hours than in Group I 
patients. The incidence of adverse effects was higher in Group I than in Group 
II. 
[24]
 
             Fareed Ahmed.et. al. 2010 conducted a study to determine the effects 
of transdermal nitroglycerine patch on intrathecal neostigmine.  Patients were 
allocated into four groups with Group I received 15 mg bupivacaine 
intrathecally,  Group II received 15mg of bupivacaine with 5μg neostigmine 
intrathecally, patients in Group III received 15mg of  bupivacaine with 1ml of 
normal saline intrathecally and transdermal NTG patch (5 mg/24 hours). 
Patients in Group IV received 15 mg bupivacaine with 5µg of neostigmine 
intrathecally and transdermal NTG patch [5 mg/24 hours]. The mean duration of 
analgesia was 202.2min, 407.6min, 207.8 min and 581.6 min in  Group-1 ,  
Group -II,  Group-III, Group-IV respectively
. [25] 
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   ANATOMICAL CONSIDERATIONS OF SPINAL ANAESTHESIA 
               Knowledge of the anatomy of vertebral column and of the lumbar 
vertebrae in particular is essential for anaesthesiologists. 
CERVICAL VERTEBRA- 7 
THORACIC VERTEBRA- 12 
LUMBAR VERTEBRA- 5 
SACRAL VERTEBRA- 5 (fused) 
COCCYX- 4 (fused) 
  A typical vertebra is composed of following parts: 
1.  BODY or the base anteriorly, which bears the weight. 
2. THE ARCH, which surrounds the cord laterally and posteriorly 
            consisting of lamina and pedicles. 
3. There are seven processes or projections 
           a. Three muscular process – two transverse and one spinous. 
           b .Four articular processes – two upper and two lower. 
                        Vertebra differs in shape and size at the various levels. The first cervical 
vertebra, the atlas, lacks a body and has unique articulations with the base of the 
skull and the second vertebra. The second vertebra, also called the axis, 
consequently has atypical articulating surfaces. All 12 thoracic vertebrae 
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articulate with their corresponding rib. Lumbar vertebrae have a large anterior 
cylindrical vertebral body. The spinal canal is defined anteriorly by the vertebral 
body, laterally by the pedicles and transverse processes, and posteriorly by the 
lamina and spinous processes. The laminae extend between the transverse 
processes and the spinous processes and the pedicle extends between the 
vertebral body and the transverse processes.   
              The individual vertebral bodies are connected by the intervertebral 
disks. There are four small synovial joints at each vertebra, two articulating with 
the vertebra above it and two with the vertebra below. These are the facet joints, 
which are adjacent to the transverse processes. The pedicles are notched 
superiorly and inferiorly, these notches forming the intervertebral foramina, 
from which the spinal nerves exit. Sacral vertebrae normally fuse into one large 
bone, the sacrum, but each one retains discrete anterior and posterior 
intervertebral foramina. The laminae of S5 and all or part of S4 normally do not 
fuse, leaving a caudal opening to the spinal canal, the sacral hiatus.  
            Identifying individual vertebrae is important for correctly locating the 
desired interspace for epidural and spinal blockade. The spine of C7 is the first 
prominent spinous process encountered while running the hand down the back 
of the neck. The spine of T1 is the most prominent spinous process and 
immediately follows C7. The 12th thoracic vertebra can be identified by 
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palpating the 12th rib and tracing it back to its attachment to T12. A line drawn 
between the iliac crests crosses the body of L5 or the L4-L5 interspaces. 
             
 
                    
Fig-1: Anatomy of lumbar spine 
 
13 
 
CONTENTS OF VERTEBRAL CANAL: - 
1. Spinal cord and meninges. 
2. Cerebrospinal fluid. 
3. Spinal nerve roots. 
4. Blood vessels and areolar tissue. 
SPINAL CORD: - 
  Medulla oblongata continues as spinal cord below the level of foramen 
magnum and it tapers off into conical extremity known as Conus Medullaris. 
Due to differential growth of vertebral column and spinal cord the lumbosacral 
nerve roots are considerably elongated to reach their respective intervertebral 
foramen which forms the Cauda Equina. From the apex of conus medullaris, 
delicate fibrous filaments descend towards first segment of coccyx, which is 
called Filum Terminale. 
 At birth, the tip of the spinal cord lies at the level of lower border of third 
lumbar vertebra. In adults spinal cord ends at lower border of L1.Anterior and 
posterior nerve root arises from the spinal cord, joins together to form spinal 
nerve and exit through the corresponding intervertebral foramen. The portion of 
the spinal cord that gives rise to all of the rootlets of a single spinal nerve is 
called a cord segment. The skin area innervated by a given spinal nerve and its 
corresponding cord segment is called a dermatome. The sympathetic neurons 
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run with the corresponding spinal nerve to a point just beyond the intervertebral 
foramen where they exit to join the sympathetic chain ganglia.           
 
Fig:2-Termination of spinal cord.. 
THE MENINGES: - 
Surrounding the spinal cord in the bony vertebral column are three 
membranes (from within to the periphery), the piamater, arachnoid mater and 
duramater.            
 The piamater is a highly vascular membrane that closely invests the spinal 
cord. Linea splendens is formed by pia which is thickened anteriorly and it runs 
along the anterior median fissure. The extension of piamater on either side 
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forms the Ligamentum denticulatum . The posterior subarachnoid septum is an 
extension of piamater from posterior median sulcus towards the dura.  Pia mater 
continues down as the filum terminale, which extends into the coccyx piercing 
the lower end of duramater and carries with it a covering of dura. 
 
                               
                            Fig-3: Cross section of spinal cord 
               The arachnoid mater is the inner most layer, a thin membrane which 
sends projection along with each spinal nerve root. Superiorly it is continuous 
with arachnoid of brain.  Between the two innermost membranes is the 
subarachnoid space. In this space are the cerebrospinal fluid, spinal nerve roots, 
blood vessels that supply the spinal cord and the denticulate ligaments. 
Although at the lower border of  L1 spinal cord ends, subarachnoid space 
continues upto S2.  
             The outermost membrane in the spinal canal is the longitudinally 
organized fibro elastic membrane, the duramater. This layer is the direct 
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extension of the cranial duramater and extends as the spinal duramater from the 
foramen magnum to S2, where the filum terminale attaches it to the coccyx.  
             Surrounding the duramater is the epidural space which extends from the 
foramen magnum to the sacral hiatus.  Posterior to the epidural space is the 
ligamentum flavum (the so-called yellow ligament), which also extends from 
the foramen magnum to the sacral hiatus. Although classically portrayed as a 
single ligament, it is really composed of two ligamenta flava, the right and the 
left, which join in the middle and form an acute angle with a ventral opening.   
             Immediately posterior to the ligamentum flavum is the interspinous 
ligament. Supraspinous ligament which extends from the external occipital 
protuberance to the coccyx lies posterior to these structures. Lumbar puncture is 
routinely done below the L2 vertebrae down to the L5-S1 interspace to avoid 
damaging the spinal cord which ends at the lower border of LI in adults. 
TABLE:1-   Ligamentum Flavum at Different Vertebral Levels 
 
      Fig:4—Ligaments of vertebral column 
                       
Site Thickness of Ligament  
Cervical 1.5-3mm 
Thoracic 3-5mm 
Lumbar 5-6mm 
Caudal 2-6mm 
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CEREBROSPINAL FLUID: - 
       It is normally clear and colourless and fills all the cavities and spaces 
around the central nervous system. It is isotonic with plasma. It is secreted 
mainly by choroid plexus of Lateral ventricle and is reabsorbed by arachnoid 
villi and granulations. In normal adults cerebrospinal fluid is formed at 25ml/hr 
or 500ml/day. There is replacement of total spinal fluid under normal 
physiological conditions every 6hrs. 
Table:2- Physical characteristics of cerebrospinal fluid 
pH 7.4 
Specific gravity  at body temperature 
  
1.007  
 Density 1.0003g/ml 
Baricity 1.000 
Pressure in supine position 8-12mm Hg 
Cells 3-5/cu.mm 
Proteins 20 mg/dl 
Glucose 45-80 mg/dl 
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BLOOD SUPPLY OF SPINAL CORD: - 
 The blood supply to the spinal cord and nerve roots is derived from a 
single anterior spinal artery and paired posterior spinal arteries. The anterior 
spinal artery is formed from the vertebral artery at the base of the skull and 
courses down along the anterior surface of the cord. The anterior spinal artery 
supplies the anterior two-thirds of the cord, whereas the two posterior spinal 
arteries supply the posterior one-third. The posterior spinal arteries arise from 
the posterior inferior cerebellar arteries and course down along the dorsal 
surface of the cord medial to the dorsal nerve roots. 
          The anterior and posterior spinal arteries receive additional blood flow 
from the intercostal arteries in the thorax and the lumbar arteries in the 
abdomen. One of these radicular arteries is typically large; the artery of 
Adamkiewicz, or arteria radicularis magna, arising from the aorta .It is typically 
unilateral and nearly always arises on the left side, providing the major blood 
supply to the anterior, lower two-thirds of the spinal cord. Injury to this artery 
can result in the anterior spinal artery syndrome. 
          It results in impaired motor function on ipsilateral side with bowel and 
bladder incontinence. Sensory impairment occurs occasionally with impairment 
of pain and temperature on contralateral side. 
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                Fig: 6- Blood supply of spinal cord. 
PHYSIOLOGY  OF SUBARACHNOID BLOCK                                                                                                                                                                
      The average CSF volume in the adult ranges from 120-150 ml of 
which 35 ml is  in the ventricles, 25 ml is in the cerebral subarachnoid space and 
75 ml is in the spinal subarachnoid space.  The cerebrospinal fluid plays an 
important role in spinal anaesthesia as media for dispersion of the local 
anaesthetic drug to the spinal nerves.        
         Spinal needles fall into two main categories: those that cut the 
duramater and those with a conical tip. The former include the Quincke-
Babcock needle, and the latter Whitacre and Sprotte.The pencil point needles 
requires more force to insert and give better ―feel‖ of the tissues penetrated and 
they do not deviate much from intended pathway. 
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Fig: 7- Types of spinal needles 
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 Three sites of action of local anaesthetics placed in the subarachnoid 
space are identified in order of importance:                                                           
1. Primary – on the nerve roots of spinal cord.         
2. Secondary – on dorsal root ganglia and posterior – anterior horn synapses.     
3. Limited and incomplete – in spinal cord parenchyma on ascending and 
descending tracts. 
Injection of local anaesthetic solution into the spinal CSF allows access to 
sites of action, both within the spinal cord and the peripheral nerve roots. The 
nerve roots leaving the spinal canal are not covered by epithelium and are 
readily exposed to the local anaesthetic within the CSF. Therefore afferent 
impulses leaving via the nerve roots are blocked during spinal anaesthesia. 
Local anaesthetics block sodium channels and propagation of action potential in 
spinal nerve roots. There are also multiple potential actions of local anaesthetics 
within the spinal cord at different sites. Local anaesthetics can exert sodium 
channel block within the dorsal and ventral horns, inhibiting generation and 
propagation of electrical activity.  
Zone of Differential Blockade:  
Sensory: In subarachnoid block sensory fibers are blocked two to three 
segments below sympathetic fibers.  
Motor: Level of motor anaesthesia averages two segments below sensory 
anaesthesia. 
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Order of blocking nerve fibers: 
1. Autonomic preganglionic B fibers. 
2. Temperature fibers- cold before warmth. 
3. Pinprick fibers. 
4. Fibers conveying pain greater than pin prick. 
5. Touch fibers. 
6. Deep pressure fibers. 
7. Somatic motor fibers. 
8. Fibers conveying vibratory sense and proprioceptic impulses. 
              During recovery, sensations return in the reverse order, but it has been 
suggested that sympathetic activity returns before sensation. 
SPREAD OF LOCAL ANAESTHETICS IN SUBARACHNOID SPACE 
              The local anaesthetic solution is diluted by CSF. Spread is also 
determined by the baricity of the injected solution. Baricity is a ratio comparing 
the density of a local anaesthetic solution at a specified temperature to the 
density of CSF at the same temperature. A hypobaric solution has a baricity less 
than 1.000. A hyperbaric solution has a baricity greater than 1.000. Hypobaric 
and Hyperbaric solutions are prepared from isobaric solutions by the addition of 
various amounts of sterile distilled water and dextrose respectively. Isobaric 
solutions do not move under the influence of gravity in the CSF. Hyperbaric 
solutions, being heavier than CSF, settle to the most dependent aspect of the 
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subarachnoid space, which is determined by the position of the patient. 
Hypobaric solution floats up against the gravity. 
TABLE – 3:  Baricity of Solutions Commonly Used for Spinal Anaesthesia 
▪HYPERBARIC SOLUTIONS BARICITY 
Tetracaine: 0.5% in 5% dextrose                 1.0133 
Bupivacaine: 0.75% in 8.25% dextrose         1.0227 
Lidocaine: 5% in 7.5% dextrose                       1.0265 
Procaine: 10% in water                                     1.0104 
▪ISOBARIC  
Tetracaine: 0.5% in normal saline 0.9997 
Bupivacaine: 0.75% in normal saline 0.9988 
▪HYPOBARIC  
Tetracaine: 0.2% in water   0 .9922 
Bupivacaine: 0.3% in water   0.9946 
Lidocaine: 0.5% in water    0.9985 
            
              Baricity is important in determining local anaesthetic spread and thus 
block height because gravity causes hyperbaric solutions to flow downward in 
CSF to the most dependent regions of the spinal column, whereas hypobaric 
solutions tend to rise in CSF. In contrast, gravity has no effect on the 
distribution of truly isobaric solutions. Thus, the anaesthesiologist can exert 
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considerable influence on block height by choice of anaesthetic solution and 
proper patient positioning.  
                  Spinal block can be restricted to the sacral and low lumbar 
dermatomes (―saddle block‖) by administering a hyperbaric local anaesthetic 
solution with the patient in the sitting position or by administering a hypobaric 
solution with the patient in the prone jackknife position. Similarly, high thoracic 
to midcervical levels of anaesthesia can be reached by administering hyperbaric 
solutions with the patient in the horizontal and Trendelenburg positions or by 
administering hypobaric solutions with the patient in a semisitting position. 
However, this use of hypobaric solutions is not recommended because the high 
block achieved and the diminished venous return associated with the upright 
posture can lead to significant cardiovascular compromise.  
                The sitting, Trendelenberg and jackknife positions have marked 
influences on the distribution of hypobaric and hyperbaric solutions because 
these positions accentuate the effect of gravity. However, most spinal 
anaesthetics are administered as hyperbaric solutions injected while patients are 
in the horizontal lateral position after which they are turned to the horizontal 
supine position. In this situation the influence of gravity is more subtle because 
the dependent areas of the spinal column do not deviate as much from the 
horizontal. While the patient is turned laterally, gravity has a small but 
measurable effect on local anaesthetic distribution in that the hyperbaric 
solutions will produce a denser, longer lasting block on the dependent side, 
25 
 
while hypobaric solutions will have the opposite effect. This makes hypobaric 
solutions ideal for unilateral procedures performed in the lateral position (e.g., 
hip surgery). Hyperbaric solutions can be used for unilateral procedures 
performed in the supine position if the operative side is dependent during drug 
injection and the patient is left in the lateral position for at least 6 minutes.  
               Despite differences in block density and duration, peak block height 
will be comparable between the dependent and nondependent sides. When the 
patient is turned supine following hyperbaric drug injection in the lateral 
position, the normal spinal curvature will influence subsequent movement of the 
injected solution.  
              Hyperbaric solutions injected at the height of the lumbar lordosis will 
tend to flow cephalad to pool in the thoracic kyphosis and caudad to pool in the 
sacrum. Pooling of hyperbaric local anaesthetic solutions in the thoracic 
kyphosis has been evoked to explain the clinical observation that hyperbaric 
solutions tend to produce blocks with an average height in the midthoracic 
region .In addition, hyperbaric solutions have also been observed to produce 
blocks with a bimodal distribution, that is, one group of patients with blocks 
centered in the low thoracic region and a second group of patients with blocks 
centered in the high thoracic region. The presumed explanation for this 
observation is that the lumbar lordosis produces ―splitting‖ of the local 
anaesthetic solution with some portion flowing caudad towards the sacrum and 
the remainder flowing cephalad into the thoracic kyphosis. The cephalad extent 
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of the block then depends on what fraction of the injected drug flows cephalad. 
Consistent with this hypothesis is the fact that eliminating the lumbar lordosis 
by maintaining the hips flexed has been shown to significantly reduce or 
eliminate the bimodal distribution of blocks without affecting maximal block 
height. 
FATE OF LOCAL ANAESTHETICS IN SUBARACHNOID SPACE   
 Following injection of local anaesthetic solution into subarachnoid space, 
its concentration falls rapidly. The initial steep fall is due to mixing with CSF 
and subsequent absorption into nerve roots and spinal cord. The regress of local 
anaesthetic solution following subarachnoid injection is primarily by vascular 
absorption. Depending on the type of the drug used, it is metabolized in plasma 
by cholinesterase [ester local anaesthetics] or in the liver [amide local 
anaesthetic]. As duration of anaesthesia is in part, result of the rate of absorption 
of local anaesthetic from the subarachnoid space, the addition of a 
vasoconstrictor will retard absorption of the drug and thus increase the duration 
of anaesthesia. 
Physiologic Effects  
          The physiologic effects of neuraxial blocks are often misinterpreted as 
complications, which is highlighted by observers listing hypotension under 
complications of the techniques. Clear distinction should be made between the 
physiologic effects of an anaesthetic technique and complications, which imply 
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some harm to the patient. This distinction is important to determine the risk-
benefit equation of the technique in question. 
Cardiovascular Effects  
                  The sympathectomy that accompanies the spinal anaesthesia depends 
on the height of the block, with the sympathectomy typically described as 
extending for two to six dermatomes above the sensory level in spinal 
anaesthesia and at the same level with epidural anaesthesia. This 
sympathectomy causes venous and arterial vasodilatation, but because of the 
large amount of blood in the venous system (approximately 75% of the total 
volume of blood), the venodilatation effect predominates as a result of the 
limited amount of smooth muscle in venules; in contrast, the vascular smooth 
muscle on the arterial side of the circulation retains a considerable degree of 
autonomous tone. 
                 After neuraxial block–induced sympathectomy, if normal cardiac 
output is maintained, total peripheral resistance should decrease only 15% to 
18% in normovolemic healthy patients, even with nearly total sympathectomy. 
The heart rate during a high neuraxial block typically decreases as a result of 
blockade of the cardio accelerator fibers arising from T1 to T4. The heart rate 
may decrease because of a fall in right atrial filling, which decreases outflow 
from intrinsic chronotropic stretch receptors located in the right atrium and great 
veins. 
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              The clinical question of what level of decrease in arterial blood 
pressure after a neuraxial block is acceptable remains to be answered. It will 
probably remain speculative because conducting ethical human investigations 
designed to define a dose-response curve of decreased arterial blood pressure 
accompanying neuraxial blockade would be difficult.  
             Prevention of decrease in mean arterial pressure of greater than 30% has 
some basis, but it is important to remember that these data were derived from 
severely hypertensive, presumably untreated patients. For normotensive and 
treated hypertensive patients, a wider undocumented margin of safety probably 
exists. 
            After arterial blood pressure decreases to a level at which treatment is 
believed to be necessary, ephedrine, a mixed adrenergic agonist, provides more 
appropriate therapy for the noncardiac circulatory sequelae of neuraxial block 
than a pure α-adrenergic agonist does, unless the patient has a specific and 
defined blood pressure requirement. That the decrease in arterial blood pressure 
after neuraxial block can be minimized by the administration of crystalloids 
intravenously is probably not a valid concept. Specifically, 250- to 2000-mL 
preblock hydration regimens appear to temporarily increase preload and cardiac 
output without consistently increasing arterial blood pressure or preventing 
hypotension. 
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Respiratory Effects  
              Tidal volume remains unchanged during spinal anaesthesia and vital 
capacity decreases by a small amount. The decrease in vital capacity is due to 
decrease in expiratory reserve volume[ERV] related to paralysis of the 
abdominal muscles necessary for forced exhalation rather than a decrease in 
phrenic or diaphragmatic function. This minimal impact on pulmonary function 
also holds for elderly patients undergoing lumbar and thoracic epidural 
anaesthesia. 
              The rare respiratory arrest associated with spinal anaesthesia is due to 
hypotension associated hypoperfusion of respiratory centers in medulla, rather 
than phrenic nerve or other respiratory muscle paralysis. It is observed that 
apnea disappears once fluid therapy and vasopressors restore BP and cardiac 
output. 
             Neuraxial block should be used cautiously in respiratory cripples 
because of paralysis of the respiratory muscles. Except for severely 
compromised patients with respiratory failure, inspiratory muscle function 
during neuraxial blocks should be adequate to maintain ventilatory function. 
The physiologic consideration related to muscle paralysis with neuraxial block 
should focus on the expiratory muscles in these severely compromised patients 
because these muscles are important for effective coughing and clearing of 
intrapulmonary secretions.
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Gastrointestinal Effects 
                Another organ system affected during neuraxial blockade is the 
gastrointestinal tract. Nausea and vomiting may be associated with neuraxial 
block in up to 20% of patients and are primarily related to gastrointestinal 
hyperperistalsis caused by unopposed parasympathetic (vagal) activity. Atropine 
is effective in treating nausea associated with high (T5) subarachnoid 
anaesthesia.
 
This gastrointestinal hyperperistalsis has the advantage of providing 
excellent surgical conditions because of a contracted gut. An often-cited 
advantage of regional anaesthesia in patients with compromised gastrointestinal 
function (e.g., hepatic dysfunction) is that less physiologic impairment is 
possible than with general anaesthesia.  
               Nevertheless, it appears that if intra-abdominal surgery is performed, 
the magnitude of the decrease in hepatic blood flow parallels the site of surgery 
rather than the anaesthetic technique chosen. The decrease in hepatic blood flow 
during spinal anaesthesia parallels the decrease in mean arterial blood pressure.  
Renal Function  
                Renal function has a wide physiologic reserve. Despite small 
decreases in renal blood flow following spinal anaesthesia, the decrease is of 
little physiologic importance. One aspect of genitourinary function that is of 
clinical importance is the belief that neuraxial blocks are a frequent cause of 
urinary retention, which delays discharge of outpatients and necessitates bladder 
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catheterization in inpatients. Lower concentrations of local anaesthetic are 
necessary for paralysis of bladder function than for paralysis of motor nerves to 
the lower extremities. However, some studies do not support this belief. For 
example, in orthopedic patients undergoing hip replacement, it was 
demonstrated that bladder catheterization was no more frequent after neuraxial 
(spinal or epidural) block than after general anaesthesia and narcotic analgesics. 
In any case, it is prudent to avoid administration of excessive volumes of 
crystalloid solutions intravenously to patients undergoing spinal anaesthesia and 
to individualize the requirement for voiding before discharge in low-risk 
ambulatory surgery patients after short-acting spinal or epidural anaesthetics are 
used. 
                    Table-4: Drug Selection for Hyperbaric Spinal Anaesthesia 
Local Anaesthetic Mixture 
Dose (mg) *  Duration (min) 
To 
T10 
To T4 Plain 
Epinephrine, 
0.2 mg 
Lignocaine [5% in 7.5% dextrose] 50-60 75-100 60 75-100 
Tetracaine [0.5% in 5% dextrose] 6-8 10-16 70-90 100-150 
Bupivacaine [0.75% in 8.5% 
dextrose] 
8-10 12-20 90-120 100-150 
Ropivacaine [0.5% in dextrose] 12-18 18-25 80-110 — 
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Local Anaesthetic Mixture 
Dose (mg) *  Duration (min) 
To 
T10 
To T4 Plain 
Epinephrine, 
0.2 mg 
Levobupivacaine 8-10 12-20 90-120 100-150 
*
 Doses are for use in a 70-kg adult male of average height 
Spinal Anaesthetic Additives  
                  Some physicians are concerned that the use of additives, particularly 
vasoconstrictors, may be risky. The concept is that epinephrine and 
phenylephrine have such potent vasoconstrictive action that they place the blood 
supply of the spinal cord at risk. There are no human data supporting this 
theory. Kozody and colleagues
 
have shown that administering subarachnoid 
epinephrine (0.2 mg) or phenylephrine (5 mg) does not decrease spinal cord 
blood flow in dogs. These traditional vasoconstrictors are not the only 
adrenergomimetic agents being studied.  
               Clonidine, an α2-agonist, prolongs the motor block associated with 
tetracaine spinal anaesthesia in dogs as much as epinephrine does while 
prolonging sensory blockade for an even longer interval. The mechanism for 
this prolongation may involve vasoconstriction and antinociception from α-
adrenergic stimulation. Another drug investigated for spinal use as an additive is 
neostigmine. This acetyl cholinesterase inhibitor inhibits the breakdown of 
acetylcholine and thereby induces analgesia. It also prolongs and intensifies the 
33 
 
analgesia through release of nitric oxide in the spinal cord. Despite the side 
effect of nausea and prolongation of motor block when combining it with local 
anaesthetics, it is slowly gaining acceptance clinically. 
                 The interaction of various vasoconstrictors and local anaesthetics is 
better understood. Traditionally, epinephrine was thought to prolong tetracaine 
spinal anaesthesia but not bupivacaine or lidocaine spinal anaesthesia. This 
theory was postulated because of differences in the vasodilatory action of the 
local anaesthetic drugs; plain lidocaine and bupivacaine cause vasodilatation, 
whereas plain tetracaine does not. The original investigations of spinal 
anaesthetic duration used two-dermatome regression in the thoracic dermatomes 
to establish duration. Since that time it has become clearer that two-dermatome 
regression in the middle to high thoracic dermatomes may be misleading when 
measuring spinal anaesthetic duration in the lower thoracic and lumbar 
dermatomes. Some data indicate that lidocaine spinal anaesthesia is prolonged 
by epinephrine when measured by two-dermatome regression in the lower 
thoracic dermatomes and by occurrence of pain at the operative site for 
procedures carried out at the level of the lumbosacral dermatomes.
 
 
              When epinephrine has been compared with phenylephrine as a means 
of prolonging spinal anaesthesia, conflicting information has resulted. 
Concepcion and coworkers
 
compared epinephrine (0.2 and 0.3 mg) and 
phenylephrine (1 and 2 mg) added to tetracaine and did not find a difference in 
increased duration with the two vasoconstrictors. . Phenylephrine has been 
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shown to prolong lidocaine spinal anaesthesia, but it appears that the length of 
prolongation is more similar to that produced with epinephrine 
.
 The duration of 
bupivacaine spinal anaesthesia does not appear to be prolonged by 
phenylephrine.
 
Whichever local anaesthetic solution and additives are selected 
for subarachnoid injection, special care should be taken to ensure that the 
clinician knows what substance is being injected and that all procedures have 
been carried out aseptically. 
THE ROLE OF NEURAXIAL ANAESTHESIA IN ANAESTHETIC 
PRACTICE  
           Almost all operations below the neck can be performed under neuraxial 
anaesthesia. However, because intrathoracic, upper abdominal and laparoscopic 
operations can significantly impair ventilation, general anaesthesia with 
endotracheal intubation is also necessary. So why do we need a regional 
anaesthetic for these cases, or for any other cases? 
 Some clinical studies suggest that postoperative morbidity and possibly 
mortality may be reduced when neuraxial blockade is used either alone or in 
combination with general anaesthesia in some settings. Neuraxial blocks may 
reduce the incidence of venous thrombosis and pulmonary embolism, cardiac 
complications in high-risk patients, bleeding and transfusion requirements, 
vascular graft occlusion, and pneumonia and respiratory depression following 
upper abdominal or thoracic surgery in patients with chronic lung disease. 
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                 Neuraxial blocks may also allow earlier return of gastrointestinal 
function following surgery. Proposed mechanisms include amelioration of the 
hypercoagulable state associated with surgery, sympathectomy-mediated 
increases in tissue blood flow, improved oxygenation from decreased splinting, 
enhanced peristalsis, and suppression of the neuroendocrine stress response to 
surgery.  
               For patients with coronary artery disease, a decreased stress response 
may result in less perioperative ischemia and reduced morbidity and mortality. 
The increasing use of perioperative β-blockade to reduce perioperative cardiac 
complications, however, may minimize or eliminate the potential advantage of 
neuraxial anaesthesia in this setting. Reduction of parenteral opioid 
requirements may decrease the incidence of atelectasis, hypoventilation, and 
aspiration pneumonia.  
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Table: 5- CONTRAINDICATIONS OF SPINAL ANAESTHESIA 
Absolute  
Infection at the site of injection 
Patient refusal 
Coagulopathy or other bleeding diathesis 
Severe hypovolemia 
Increased intracranial pressure 
Severe aortic stenosis 
Severe mitral stenosis 
Relative  
Sepsis 
Uncooperative patient 
Preexisting neurological deficits 
Demyelinating lesions 
Stenotic valvular heart lesions 
Severe spinal deformity 
Controversial  
Prior back surgery at the site of injection 
Inability to communicate with patient
1
 
Complicated surgery 
Prolonged operation 
Major blood loss 
Maneuvers that compromise respiration 
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Table:6- Factors Influencing Block Height 
 
Controllable Factors  
 
 Dose (volume × concentration) 
 
 Site of injection along the neuraxis 
 
 Baricity of the local anaesthetic solution 
 
 Posture of the patient 
Factors Not Controllable  
 
 Volume of cerebrospinal fluid 
 
 Density of cerebrospinal fluid 
 
 
Factors Probably Unrelated to Height of the Spinal Anaesthetic Block 
 
 
 Added vasoconstrictor 
 
 Coughing, straining, or bearing down  
 
 Barbotage 
 
 Rate of injection  
 
 Needle bevel 
 
 Gender 
 
 Weight 
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COMPLICATIONS OF SUBARACHNOID BLOCK 
  Immediate complications:-                                                                                    
 Hypotension. 
 Bradycardia. 
 Toxicity due to intravascular injection. 
 Allergic reaction to local Anaesthetic. 
 Hypoventilation (brain stem hypoxia). 
Late complications:-                                                                                   
Backache                                                                                                                                                                        
Postoperative backache is common following spinal and epidural anaesthesia. 
The etiology of backache is not clear, although needle trauma, local anaesthetic 
irritation, and ligamentous strain secondary to muscle relaxation have been 
offered as explanations. 
Postdural Puncture Headache 
The incidence of PDPH is as high as 25%. PDPH is characteristically mild or 
absent in supine position but becomes severe on standing or head end elevation. 
Occasionally cranial nerve symptoms (e.g. diploplia, tinnitis) and nausea and 
vomiting are also present. The headache is due to loss of cerebrospinal fluid 
through the meningeal hole created by the spinal needle. In the upright position 
the brain sags in the cranial vault putting traction on pain-sensitive structures. 
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Traction on cranial nerves is believed to cause the cranial nerve palsies 
occasionally seen. 
                The incidence of PDPH decreases with increasing age  and with the 
use of small diameter spinal needles with noncutting tips. Inserting cutting 
needles with the bevel aligned parallel to the long axis of the meninges has also 
been shown to decrease the incidence of PDPH. Some authors have suggested 
that parallel insertion spreads dural fibers, whereas perpendicular insertion cuts 
the fibers resulting in a larger meningeal hole. However, the collagen fibers of 
the dura mater are arranged randomly; therefore, as many fibers will be cut with 
parallel insertion as with perpendicular insertion. A more likely explanation 
arises from the fact that the dura mater is under longitudinal tension. Thus, a 
slit-like hole oriented perpendicular to this longitudinal tension will tend to be 
pulled open while a hole oriented parallel to this tension will be pulled closed.  
              Some studies have suggested that women are at greater risk of 
developing PDPH. However, if age differences are accounted for, there does not 
appear to be a gender difference in the incidence of PDPH. Finally, use of fluid, 
instead of air, for loss of resistance during attempted epidural anaesthesia does 
not alter the risk of accidental meningeal puncture, but does markedly decrease 
the risk of subsequently developing PDPH. PDPH usually resolves 
spontaneously in a few days to a week for most patients. However, there are 
reports of PDPH persisting for months following meningeal puncture. Bed rest 
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and analgesics are the mainstay of conservative management. Caffeine has also 
been shown to provide symptomatic relief. 
Table-7:  Relationships Among Variables and PDPH 
Factors That May Increase the Incidence of Post–spinal Puncture 
Headache 
Age Younger more frequent 
Gender Females > males 
Needle size Larger > smaller 
Needle bevel 
Less when the needle bevel is placed in the long axis of the 
neuraxis 
Pregnancy More when pregnant 
Dural punctures 
(no.) 
More with multiple punctures 
Factors Not Increasing the Incidence of Post–spinal Puncture Headache 
Continuous spinals 
Timing of ambulation 
 
Epidural Blood Patch. 
              Epidural blood patch forms a clot over the meningeal hole, and thus 
prevents further CSF leak 10 to 20 mL of autologous blood is injected 
aseptically into epidural space at or near the interspace at which meninges was 
punctured. This is effective in relieving symptoms within 1 to 24 hours in 85% 
to 95% of patients; ~90% of patients who fail an initial blood patch will respond 
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to a second patch. The most common side effects of blood patch are backache 
and radicular pain, although transient bradycardia and cranial nerve palsies have 
also been reported. 
                The timing of epidural blood patch has been controversial. Early 
studies suggested that prophylactic blood patch in patients at high risk for PDPH 
was ineffective. This led several authors to suggest that blood patch should not 
be performed before patients develop symptoms of PDPH. Subsequent studies, 
which used larger volumes of blood in the epidural space (15 to 20 mL), have 
shown that prophylactic blood patch is effective in preventing PDPH in patients 
in whom the meninges were accidentally punctured during attempted epidural 
anaesthesia. Prophylactic blood patch is not appropriate for most patients but is 
worth considering in high-risk outpatients for whom a return trip to the hospital 
for epidural blood patch would be difficult.  
                Epidurally administered fibrin glue has been shown to be an effective 
alternative to blood .The incidence of postdural puncture headache decreases as 
patient age increases. When using beveled needles, the incidence is higher than 
average at any given age if the needle is inserted perpendicular to the spinal 
meninges and lower if inserted parallel to the spinal meninges.   
 Hearing Loss 
                Lamberg et al demonstrated that a transient (1 to 3 days) mild 
decrease in hearing acuity [>10 dB] is common after spinal anaesthesia with an 
incidence of around 42% and a 3:1 female: male predominance. Similarly, 
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Gültekin et al demonstrated a 45% incidence of hearing impairment in subjects 
undergoing prilocaine spinal anaesthesia but a much lower incidence (18%) in 
patients having bupivacaine spinal anaesthesia. The mechanism of hearing loss 
in these studies is not clear.  
Total Spinal 
                 Total spinal anaesthesia occurs when local anaesthetic injected 
intrathecally spreads cephaled enough to block the entire spinal cord or even the 
brainstem. Bradycardia and profound hypotension are common secondary to 
complete sympathetic blockade. Apnea may occur as a result of respiratory 
muscle paralysis or dysfunction of brainstem respiratory control centers. 
Management includes delivering 100% O2 via controlled ventilation, treating 
hypotension with intravenous fluids and vasopressors, atropine to treat 
bradycardia. If the cardiovascular and respiratory consequences are managed 
appropriately, total spinal block will resolve without sequelae. 
Neurologic Injury 
                 Multiple large series of spinal and epidural anaesthesia report that 
neurologic injury occurs in ~0.03% to 0.1% of all central neuraxial blocks, 
although in most of these series the block was not clearly proven to be 
causative. Paresthesias and motor weakness are the most common injuries, but 
cauda equina syndrome also occurs rarely. Injury results from direct needle 
trauma to spinal nerves or spinal cord, from cord ischemia, by introduction of 
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infection into the subarachnoid or epidural space, from accidental injection of 
neurotoxic drugs or chemicals, or rarely from epidural hematoma.  
                Hyperbaric 5% lidocaine has been implicated as a cause of multiple 
cases of cauda equina syndrome following subarachnoid injection through 
small-bore (―microspinal‖) catheters during continuous spinal anaesthesia. 
Hyperbaric solutions injected through these high-resistance catheters have been 
shown to produce very little turbulence and thus poor mixing of the local 
anaesthetic within the CSF. Nerve injury is believed to result from pooling of 
toxic concentrations of undiluted lidocaine around dependent cauda equina 
nerve roots.  Microspinal catheters and high concentrations of lidocaine have 
clearly been implicated in causing cauda equina syndrome, this complication 
has also occurred when using larger (20 gauge) catheters, 2% lidocaine, and 
0.5% tetracaine.  
Transient Neurologic Symptoms (TNS) 
                 In addition to cauda equina syndrome, the occurrence of transient 
neurologic symptoms (TNS) or transient radicular irritation (TRI) has also 
emerged as a concern following central neuraxial blockade. Transient Radicular 
Irritation is defined as pain, paresthesia, or both in the lower limbs , buttocks 
after spinal anaesthesia and was first proposed as a recognizable entity by 
Schneider. All local anaesthetics have been shown to cause TRI although the 
risk appears to be greater with lidocaine than other local anaesthetics. In a large 
epidemiologic study of nearly 2,000 patients, Freedman et al characterized the 
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clinical picture of TRI. They found that patients receiving lidocaine were 
significantly more likely to develop TRI than were patients receiving spinal 
tetracaine or bupivacaine although TRI did occur with these latter two drugs as 
well. Additional risk factors for TRI included surgery in the lithotomy position 
when lidocaine, but not when bupivacaine or tetracaine, was used, and 
outpatient status; obesity was a borderline risk factor. Variables shown not to 
increase the risk of TRI included lidocaine dose, type of spinal needle, addition 
of epinephrine to lidocaine, paresthesia, hypotension, and blood tinged CSF 
among others. The pain usually resolved spontaneously within 72 hours but a 
very few patients required 6 months. 
              The mechanism responsible for TRI is unknown; however, it would be 
inappropriate to conclude that TRI is simply a milder manifestation of cauda 
equina syndrome. Differences in clinical presentation, risk factors, and so on 
suggest that these are not simply two points along a continuum of the same 
process. 
          CIRCULATORY EFFECTS OF SUBARACHNOID BLOCK 
             The subarachnoid block can influence the cardiovascular system, as 
follows. 
1) Vasodilatation of resistance and capacitance vessels. 
2) Block of cardiac efferent sympathetic fibers from T1 to T4 resulting in 
loss of chronotropic and inotropic drive and fall in cardiac output. 
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3) A further cause of bradycardia is the lowering of pressure in the right 
atrium consequent to diminished venous return (Bain Bridge reflex). 
4) Bezold–Jarisch reflex where by baroreceptors located in the 
inferoposterior wall of the left ventricle respond to increase in ventricular 
contractility induced by reduction in preload and ventricular volume. 
Stretch of these baroreceptors paradoxically increases vagal output 
resulting in bradycardia. 
5) Vasodilatation and -adrenergic blockade of myocardium with fall in 
cardiac output, following systemic absorption of the local anaesthetic 
drug. 
PHYSIOLOGY OF PAIN 
            The widely accepted definition of pain was developed by a taxonomy 
task force of the International Association for the Study of Pain: ―Pain is an 
unpleasant sensory and emotional experience that is associated with actual or 
potential tissue damage or described in such terms.‖ 
AUTONOMIC NERVOUS SYSTEM RESPONSES:- 
            Painful stimulation may evoke reflex increase in sympathetic nervous 
system efferent activity. It is possible that associated vasoconstriction leads to 
acidosis, tissue ischemia, and release of chemicals that further activate pain 
receptors. Resulting sustained, painful stimulation produces further increases in 
sympathetic nervous system activity and the vicious cycle termed reflex 
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sympathetic dystrophy (complex regional pain syndrome) may develop.  After 
certain types of nerve injury, pain may occur without activation of pain 
receptors. Spontaneous firing that occurs from injured peripheral nerves, 
especially in response to sympathetic nervous system stimulation may reflect a 
proliferation of alpha-adrenergic receptors on the increased number of neuroma 
sprouts (Devor, 1983). Spontaneous firing may also occur from dorsal root 
ganglia whose peripheral projections have been interrupted, as after nerve 
transection or limb amputation. 
Neuromodulators: 
              The activity of dorsal horn relay and projection neurons is modulated 
by several inhibitory inputs, including chemical modulators. They are as 
follows: 
1. Gamma amino butyric acid (GABA): It is a major source of pre and post 
synaptic inhibition of nociceptive input. The interneurons releasing GABA are 
concentrated in the superficial laminae of the dorsal horn. 
2. Glycine: Intrinsic neurons containing glycine are also inhibitory but are more                                                   
widely distributed in the gray mater. 
3. Endogenous opioids: There are three families of endogenous opioids: 
            (a) β endorphin. 
            (b) (leu) enkephalin and (met) enkephalin.              
            (c) Dynorphin A and B. 
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              These three families of opioid peptides have distinct anatomical 
distribution in the CNS and differing affinities for opioid receptors which are 
classified into μ, δ, κ, ε and ζ receptors. 
4. Descending pathway originating in the brainstem also modulate the activity 
of dorsal horn relay and projection neurons. Descending catecholaminergic 
pathways from locus coeruleus and ventrolateral horns and medulla inhibit 
nociceptive spinal neurons. Descending control may also be derived from 
dopamine containing regions of the hypothalamus and caudal thalamus.  
5. Cholinergic binding sites have been identified in the dorsal horn. These spinal 
cholinergic receptors are involved in mediating antinociceptive effects. These 
antinociceptive effects are independent of opioid and α receptor system and 
these receptors are primarily muscarinic and not nicotinic cholinergic receptors. 
Acetylcholine has been found to act upon these muscarinic receptors which are 
of subtype M1 and M3 . 
METHODS OF PAIN MEASUREMENT: 
            Merskey of International Association for the Study of Pain (IASP) 
defined pain "as the sensory and emotional experience associated with actual or 
potential tissue damage or described in terms of such damage". One cannot 
determine for the individual patient how much nociception occurs in response to 
tissue damage for which we have to rely on the expression of the patient to 
accurately measure the subjective nature of pain. 
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 Loser, of multidisciplinary pain centre, University of Washington put 
forward a multifaceted model. The core of the model is the immeasurable 
nociception resulting from tissue damage. The next layer is the human 
experience of emotional and sensory components integrated pain which is not 
available for direct inspection. Pain leads to suffering and suffering leads to 
painful behaviours which is available for observation in the form of 
-Withdrawing, Grimacing, Crying, Asking for analgesics. 
Thus if one relies on the patient's report of pain it is possible to measure pain 
intensity and the response to analgesic medications. 
Introspective Method: 
           Patient or trained attender attempts to assess pain. 
Behavioural Method: 
Some physical parameters which get altered in the presence of pain are 
objectively measured and correlated with the severity of pain like tachycardia, 
tachypnea and increased blood pressure. 
PAIN AS SELF -REPORT ON A SINGLE DIMENSION: 
         Verbal Descriptor Scales: Melzack and Torgerson introduced the 
following scale for pain intensity; ―Mild, Discomforting, Distressing, Horrible, 
Excruciating." 
        Numeric Rating Scale (NRS): Here patients are asked to indicate how 
strong their pain is on a scale from 0 to 10 on which 0 represents "no pain at all" 
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and 10 "the worst pain imaginable". 
        Visual Analogue Scale (VAS): Currently, the most commonly used 
method, first described by AITKEN in 1966.The subject makes a mark on a 
10cms line – horizontal or vertical, one end of which is marked as "No pain" 
and the other as "The worst pain one can imagine". The position of the mark on 
the line measures how much pain the subject experiences. 
 
       Oral Analogue Scale (OAS): First put forward by AUSTIN et.al.It is a 
simple and clinically relevant rating scheme. Absence of pain, presence of pain, 
and if the patient desired more analgesics are rated 0, 1 and 2 respectively.  
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PAIN AS SELF-REPORTS ON MULTIPLE DIMENSIONS: 
       McGill Pain Questionnaire: It scales pain in three dimensions: Sensory, 
Affective and Evaluative. 
      West Haven-Yale Multidimensional Pain inventory: This has been 
designed to be briefer and more classical in its psychometric approach. 
       Brief Pain Inventory: is a quick, multidimensional pain measurement that 
has demonstrated reliability and validity. 
       Memorial Pain Assessment Card: It scales pain, pain relief and mood on 
VAS and adds a set of adjectives reflecting pain intensity. 
      Cross-Modality Matching: a psychophysical technique in which a sensory 
experience is quantified by matching it to the experience of a precisely 
controlled stimulus in a different sensory modality. 
        Pain Perception Profile: is based on cross modality matching. 
               The preoperative personality assessment is also helpful in assessing the 
patient‘s psychological background and his psycho to surgery and the pain that 
follow it. Although there is no absolute consensus on how clinical pain should 
be measured, there is enough agreement that clinicians and researchers do not 
have to despair of being able to measure the subjective phenomenon of pain. 
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METHODS OF POSTOPERATIVE PAIN RELIEF: 
Preventive Analgesia 
           Central sensitization and hyperexcitability develop after the surgical 
incision and result in amplification of postoperative pain. Although 
experimental studies convincingly confirm the concept of preemptive analgesia 
in decreasing post injury pain, the results of clinical trials are mixed.
 
Definitions 
of preemptive analgesia include what is administered before the surgical 
incision, what prevents the establishment of central sensitization resulting from 
incisional injury only (i.e., intraoperative period), what prevents central 
sensitization resulting from incisional and inflammatory injury (i.e., 
intraoperative and postoperative periods), or the entire perioperative period 
encompassing preoperative interventions, intraoperative analgesia, and 
postoperative pain management (i.e., preventive analgesia).        
         Timing of the intervention
 
may not be as clinically important as other 
aspects of preventive analgesia (i.e., intensity and duration of the intervention). 
An intervention administered before the surgical incision is not necessarily 
preemptive if it is incomplete or insufficient such that central sensitization is not 
prevented.  
         A variety of drugs and technique
]
 have been used to study preemptive 
analgesia. By preventing central sensitization, preemptive analgesia along with 
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intensive multimodal analgesic interventions
 
could theoretically reduce acute 
postoperative pain/hyperalgesia and chronic pain after surgery. 
Multimodal Approach to Perioperative Recovery  
            The analgesic benefits of controlling postoperative pain are generally 
maximized when a multimodal strategy to facilitate the patient's convalescence 
is implemented.The use of epidural anaesthesia and analgesia is an integral part 
of the multimodal approach because of the superior analgesia and physiologic 
benefits conferred by epidural analgesia. 
           A multimodal approach to perioperative recovery to control postoperative 
pathophysiology and facilitate rehabilitation may result in accelerated recovery 
and decreased length of hospitalization. Patients undergoing major abdominal or 
thoracic procedures and who participate in a multimodal strategy have a 
reduction in hormonal and metabolic stress, preservation of total-body protein, 
shorter times to extubation, lower pain scores, earlier return of bowel function, 
and earlier fulfilment of intensive care unit discharge criteria. 
TREATMENT METHODS: 
          Many options are available for treatment of postoperative pain. By 
considering patients‘ preferences and individualized assessment of the risks and 
benefits of each treatment modality, the clinician can optimize the postoperative 
analgesic regimen for each patient. 
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1) Systemic Analgesic Techniques: 
a) Opioids: Opioid analgesics are cornerstone options for the treatment of              
postoperative pain. Opioids may be administered by oral, intravenous, 
intramuscular, subcutaneous, transcutaneous or transmucosal routes. 
b) Nonopioids Analgesics: 
c) Nonsteroidal Anti-inflammatory Agents (NSAIDS): Used as sole 
agents, NSAIDS generally provide effective analgesia for mild to 
moderate pain. 
2) Regional Analgesic Techniques: 
a) Central Neuraxial Blockade: The administration of local 
anaesthetics,  opioids, spinal adjuvants such as neostigmine or a 
combination neuraxially (subarachnoid or epidurally) is an excellent 
technique for managing postoperative pain following abdominal, pelvic, 
thoracic, or orthopaedic procedures on the lower extremities.  
b) Peripheral Regional Analgesia: This includes various nerve blocks.  
It can be administered as single shot or continuous infusions through 
peripheral nerve catheters.  
3) Other Techniques: such as transcutaneous electrical nerve stimulation           
(TENS), acupuncture and psychological approaches can be used . 
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PHARMACOLOGY OF BUPIVACAINE 
INTRODUCTION:- 
           It is an aminoamide local anaesthetic..It is chemically known as 1-butyl 
2-piperidyl formo-2‘6‘-xylidine hydrochloride.It was first synthesised by 
Swedish investigator Boaf Ekenstam.  
CHEMICAL STRUCTURE:- 
 
 
Cture of  
Fig:8- Chemical structure of bupivacaine 
PHYSICAL AND CHEMICAL PROPERTIES:- 
1. Chemically it is an amide – 2,6 methyl amide 
2. Molecular weight - 325 
3. pH of saturated solution - 5.2 
4. Specific gravity - 1.025 at 370 C 
5. Stability and sterilization - highly stable, can withstand repeated 
autoclaving. 
6. Melting point - 247 to 2580 C. 
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MECHANISM OF ACTION:- 
Mechanism of action of bupivacaine is similar to that of any other local 
anaesthetics. The primary action of local anaesthetic is on the cell membrane of 
the axon on which it produces electrical stabilization. The large transient 
increase in permeability to sodium ions necessary for propagation of the impulse 
is prevented. Thus the resting membrane potential is maintained and 
depolarization in response to stimulation is inhibited.  
DISTRIBUTION:- 
Rapid distribution phase (alpha)-In this phase the drug is distributed to 
highly vascular region, 
 
t
1/2
 being 2.7 minutes. Slow disappearance phase (beta)-
In this phase the drug distributes with slowly equilibrating tissues, t
1/2
 of Beta is 
28 minutes .Biotransformation and excretion phase- half time of   is 3.5 hours. 
BIOTRANSFORMATION:- 
Possible pathways of metabolism of bupivacaine include aromatic 
hydroxylation and conjugation. Only the N-alkylated metabolite, N-butyl 
bupivacaine has been measured in blood or urine after epidural or spinal 
anaesthesia. Alpha-1 acid glycoprotein is the most important plasma protein 
binding site of bupivacaine. Excretion is through the kidney 4-10% of the drug 
is excreted unchanged. 
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TOXICITY:- 
 Toxicity is related to plasma level of unbound drug and more likely due 
to inadvertent intravenous injection. Systemic toxicity reactions primarily 
involve CNS and CVS. The blood level required to produce CNS toxicity is less 
than that to produce circulatory collapse. 
CENTRAL NERVOUS SYSTEM TOXICITY:- 
           Early symptoms are dizziness, tongue paresthesia, circumoral numbness. 
Blurred vision and tinnitus usually occurs. . Skeletal muscle twitching precedes 
the onset of seizures. Respiratory arrest often follows. The excitatory reactions 
are a result of selective blockade of inhibitory pathways. Benzodiazepines and 
hyperventilation raises the threshold of local anaesthetic induced seizure 
activity. Thiopentone (1–2 mg/kg) effectively terminates seizure activity. 
Adequate ventilation and oxygenation must be maintained 
CARDIOVASCULAR TOXICITY:- 
          In general, all local anaesthetics depress myocardial automaticity. These 
effects result from direct cardiac muscle membrane changes (cardiac sodium 
channel blockade) and inhibition of the autonomic nervous system. Bupivacaine 
produces smooth muscle relaxation, which causes some degree of arteriolar 
vasodilatation. Accidental intravenous injection of bupivacaine ensues 
combination of bradycardia, heart block, and hypotension may culminate in 
cardiac arrest. 
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PHARMACOLOGY OF NEOSTIGMINE
 
INTRODUCTION:- 
Neostigmine methylsulfate was synthesized by Aeschliman and Reinest 
in1931.It is available as bromide and methylsulfate salts. 
PHYSICAL PROPERTIES:- 
It is a synthetic quaternary ammonium compound. It consists of 
carbamate moiety and quaternary ammonium Group. The former provides 
covalent bonding in acetylcholinesterase. The latter renders the molecule lipid 
insoluble so that it cannot pass through blood brain barrier. 
CHEMICAL STRUCTURE:- 
 
Fig:9- Chemical structure of Neostigmine 
INTRATHECAL NEOSTIGMINE:- 
Intrathecal neostigmine inhibits metabolism of spinally released 
acetylcholine and produces analgesia in animals and humans. It increases blood 
pressure and heart rate by direct stimulation of preganglionic sympathetic 
neurons in spinal cord. It reduces the uterine activity by β adrenergic effects and 
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reduces the uterine blood flow by α adrenergic action.  
Potency of intrathecal neostigmine is increased in post-operative period, 
because descending noradrenergic or cholinergic antinociceptive spinal system 
is activated by ongoing pain causing an increase in release of acetylcholine, 
which, in presence of neostigmine results in augmented selective analgesia. 
Neurological effects:- 
Motor weakness and reduction in deep tendon reflex are shown in 
subjects receiving high dose of neostigmine. Motor effects are consistent with 
cephalad spread of neostigmine in CSF and it is due to direct action on motor 
fibres, rather than to ischemia or neurotoxicity.  Neostigmine in large doses do 
not reduce spinal blood flow. Intrathecal neostigmine did not cause changes in 
attention, motor coordination or memory. 
Gastrointestinal effects: -   
        Vomiting and nausea occur in a dose related manner after intrathecal 
neostigmine. The most likely site of action is brain stem. A peripheral site of 
action of intrathecal neostigmine is unlikely, because plasma concentration after 
small intrathecal doses would be very low. Also systemic administration of 
glycopyrrolate was ineffective in treating the nausea. Nausea and vomiting are 
the most important side effect of intrathecal neostigmine. 
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Cardiovascular system:- 
       Higher dose can cause bradycardia. Blood pressure is minimally affected. 
Respiratory effects:- 
       Respiratory system is minimally affected even with higher doses. 
Genitourinary effects:- 
      Urinary retention has occurred after higher doses, but only for brief periods. 
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            NITROGLYCERINE TRANSDERMAL SYSTEM 
Nitroglycerine is 1,2,3-propanetriole  trinitrate. 
 
Fig-10: Chemical structure of nitroglycerine 
          Molecular weight of NTG is 227.09. It is a vasodilator of both arteries and 
veins. 
          The Nitroglycerine Transdermal System provides slow sustained release 
of nitroglycerine through skin. The rate of release of nitroglycerine is dependent 
upon the area of the system; each square centimetre of applied system delivers 
approximately 0.02 mg of nitroglycerine/ hr. Thus, the 18cm2 and 10cm2 
systems deliver approximately 0.4mg and 0.2mg of nitroglycerine/hour 
respectively. Each 10cm2 system contains 20mg of nitroglycerine. The 
transdermal NTG system delivers 12% of its initial content of nitroglycerine by 
12 hours. 
         The Nitroglycerine Transdermal System comprises of three layers. These 
layers are 1) impermeable polypropylene layer and 2) nitroglycerine in an 
adhesive acrylic- polymer matrix which acts as a source of NTG.3) A peelable 
protective layer on the outer surface which has to be removed to attach to skin. 
61 
 
 
Fig:11-Cross section of Transdermal NTG system: 
Nitroglycerine Transdermal System- Clinical Pharmacology:- 
         The action of nitroglycerine is relaxation of vascular smooth muscles and 
dilatation of peripheral veins/arteries, [mainly veins]. Venous dilatation 
promotes peripheral pooling of blood and venous return to the heart decreases. 
This reduces preload. Arteriolar dilatation decreases systemic vascular 
resistance, systolic BP, and mean BP (afterload).Vasodilatation occurs in the 
coronary arteries also. 
Pharmacokinetics:- 
         The volume of distribution of nitroglycerine is about 3.2 L/kg, and 
nitroglycerine is cleared rapidly from circulation.  The initial metabolites of 
nitroglycerine are inorganic nitrates and 1,2  and1,3-dinitroglycerol. These are 
further metabolised to mononitrates and finally to carbon dioxide and glycerol. 
Upon removing the patch, the plasma concentration declines with a half-life of 
about an hour. 
TRANSDERMAL NITROGLYCERINE IN SPINAL ANAESTHESIA 
         The transdermal NTG patch releases nitric oxide during degradation to 
organic nitrates. According  to clinical research, nitric oxide generators do not 
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produce analgesia but recent researches  provides evidence of acetylcholine, 
stimulating NO  synthesis in the spinal cord, which is necessary for the 
expression of analgesic effect secondary to the cholinomimetics.. This 
mechanism of action is mediated through second messengers like cGMP. 
Neurons in the superficial spinal dorsal horn shows decreased response after 
exposure to cGMP. Therefore, analgesic effect would be due to predominant 
action on superficial spinal cord layers.  
Precautions:- 
             Postural hypotension may occur particularly in the elderly. Hypotension 
induced by nitroglycerine may be accompanied by paradoxical bradycardia and 
this can increase the incidence of angina pectoris. 
Drug Interactions:-                                                                                                                                   
   The vasodilating effects of nitroglycerine may be additive with those of 
other vasodilators. Alcohol, in particular, has been found to exhibit additive 
effects of this variety. 
Adverse Reactions:- 
            Adverse reactions to nitroglycerine are generally dose related, and 
almost all of these reactions are the result of nitroglycerine‘s activity as a 
vasodilator. Headache, which may be severe, is the most commonly reported 
side effect. Transient episodes of light headedness occurs. Hypotension occurs 
infrequently but warrants discontinuation in some patients. 
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PATIENTS AND METHODS 
                After obtaining approval from Ethical Committee, the study was 
conducted in RAJA MIRASDAR HOSPITAL [Thanjavur medical college] over 
a period of 5 months. After obtaining informed consent, the study was 
conducted on 78 patients aged 30 to 60 years of ASA grade I and II, planned for 
hysterectomies. Patients were allocated into 3 groups, each group containing 
consisting 26 patients. 
Group C:     Patients received 15mg [3ml] of intrathecal bupivacaine. 
Group N:    Patients received 15mg [3ml] of intrathecal bupivacaine                
      and 25μg [1ml] of neostigmine. 
Group P:     Patients, in addition to 15mg [3ml] of intrathecal  bupivacaine and 
25μg [1ml] of neostigmine, received transdermal NTG patch 
[5mg/24hours] at chest wall in non-anaesthetized area 15 minutes 
after intrathecal administration of drug solution. 
             Visual analogue scale [VAS] was used as pain score, 0 = no pain and  
10 = worst pain. After preloading the patients with Ringer Lactate 10ml/kg, 
spinal anaesthesia was performed at L3-L4 level, with 25 gauge Quincke needle 
and 4ml of drug volume was injected intrathecally. 
            Sensory level was assessed by pinprick. BP was recorded every 5 
minutes during the surgery. Inj. ephedrine 6mg IV was given when systolic BP 
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decreases below 15% of base line. Pulse rate and SpO2 were observed 
continuously. Fall in heart rate below 60 per minute was treated with Inj. 
atropine 0.2mg IV. Intraoperative vomiting was treated with Inj. 
Metoclopramide 10mg IV. Postoperatively VAS score was used to assess pain 
in subjects every 30 minutes. Patients were given rescue analgesia at VAS score 
of 4. 
  Other adverse effects like vomiting, nausea, sedation bradycardia, 
hypotension, sweating, headache and palpitation were also monitored. 
 Inj Pentazocine 30 mg was administered intramuscularly as rescue 
analgesic. Duration of analgesia was calculated from the time of intrathecal drug 
administration till VAS score reaches 4. 
Data thus obtained were analyzed using Microsoft Excel software. 
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   Statistical Tools   
The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and 
 
'p'  values were calculated. Kruskul Wallis chi-square 
test was used to test the significance of difference between quantitative variables 
and Yate‘s chi square test for qualitative variables. A 'p' value less than 0.05 is 
taken to denote significant relationship. 
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RESULTS 
A : Characteristics of cases 
                                        Table 8 : Age distribution 
Age group Group C Group N Group P 
 no: % no: % no: % 
Upto 40 years  3 11.5 8 30.8 9 34.6 
41-50 years 14 53.8 14 53.8 10 38.5 
51-60 years 9 34.6 4 15.4 7 26.9 
Total 26 100 26 100 26 100 
Range 38-58 years 33-55 years 35-60 years 
Mean 48.7 years 45.2 years  46.3 years 
SD 5.6 years 6.1 years 7.3 years 
‗p‘ value 0.1348  
Not significant 
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Graph -1: Age distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 There was no statistically significant difference in the distribution of age 
among the three groups. 
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      Table- 9: Distribution of weight among the three groups 
 
 
 
 
 
 
 
 
 
Group 
Weight ( in kg) 
Range Mean SD 
Group C 45 - 70 52.9 6.1 
Group N 45 - 60 52.3 4.7 
Group P 40 - 66 51.7 5.8 
‗p‘ value 0.8163  
Not significant 
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           Graph -2: Comparison of mean weight among the three groups. 
. 
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There was no statistically significant difference between the distribution of 
weight among the three groups…………. 
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                                   Table -10: Duration of surgery 
 
Group 
Duration of surgery in minutes 
Range Mean SD 
Group C 55 - 130 90.2 18.1 
Group N 60 - 120 83.8 18.0 
Group P 60 - 120 85.1 18.4 
‗p‘ value 0.3675  
Not significant 
There is no statistically significant difference between duration of surgery 
among the three groups.. 
                        Graph-3: Mean duration of surgery in minutes..  
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                           COMPARISON OF THREE REGIMEN 
 
                                    Table 11: Changes in pulse rate 
 
Pulse rate  
Pulse rate  ‘p’ value between Groups 
Group C Group N Group P  
C,N & 
P 
 
C &N 
 
C & P 
 
N &P Mean SD Mean  SD Mean SD 
Pre 
operative 
91 10.4 90.8 11.
6 
89.2 12.8 0.7195 
Not 
significant. 
0.5701  
Not 
significant
. 
0.481  
Not 
significant. 
0.6604 
Not 
significant
. 
Intra 
operative 
90.2 11.1 86.4 10.
7 
85.9 12.7 0.1723 
Not 
significant 
 
0.0714 
Not 
significant 
0.156 
Not 
significant 
0.927 
Not 
significant 
 
Post 
operative  
87.4 10.5 87.4 11.
4 
85.6 12.6 0.7125 
Not 
significant 
0.5704 
Not 
significant 
0.5159 
Not 
significant 
0.5518 
Not 
significant 
Decrease 3.5 2.4 3.3 5.0 3.6 7.3 0.7623 
Not 
significant 
0.4809 
Not 
significant 
0.5704 
Not 
significant 
0.9416 
Not 
significant 
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There is no statistically significant difference in the heart rate among the 
three groups…..  
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      Table -12: Changes in Mean Arterial Pressure among the three groups 
 
 
MAP  
MAP of   ‘p’ value between Groups 
Group C Group N Group P  
C,N & 
P 
 
C &N 
 
C & P 
 
N &P Mean SD Mean  SD Mean SD 
Pre 
operative 
90.0 5.2 90.7 5.2 88.5 6.8 0.4273 
Not 
significant. 
0.3696  
Not 
significant. 
0.558  
Not 
significant
. 
0.234 
Not 
significant
. 
Intra 
operative 
85.7 5.5 85.8 5.4 83.3 6.7 0.2021 
Not 
significant. 
0.8836 
Not 
significant. 
0.148 
Not 
significant
. 
0.1033
Not 
significant
. 
Post 
operative  
85.7 5.6 86.9 4.6 85.1 6.6 0.7111 
Not 
significant. 
0.4474 
Not 
significant. 
0.9416 
Not 
significant
. 
0.5099 
Not 
significant
. 
Decrease 3.9 1.7 3.7 4.2 3.4 2.2 0.118 
Not 
significant. 
0.9271 
Not 
significant. 
0.1102 
Not 
significant
. 
0.4207 
Not 
significant
. 
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There is no statistically significant difference in the mean arterial pressure 
among the three groups…..
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                    Table- 13: Comparison of Duration of Analgesia 
 
 
Group 
Duration of Analgesia in minutes 
Range Mean SD 
Group C 120 - 180 150.4 15.7 
Group N 180 - 250 211.3 22.8 
Group P 200 - 400 316.3 48.0 
‗p‘ value between Groups 
C,N & P 
 
0.0001 - Significant 
C & N 0.0001 Significant 
C & P 0.0001 Significant 
N & P 0.0001Significant 
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Graph-6:  Comparison of Duration of Analgesia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Duration of analgesia was longest in Group P in comparison to other 
two groups and this difference was statistically significant. … 
 
 Duration of analgesia was longer in Group N in comparison to Group 
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       Table -14 a: Adverse effects 
 GROUP-
P 
 GROUP-
N 
 GROUP-
C 
NAUSEA 8  8  2 
VOMITING 6  7  1 
HYPOTENSION 3  2  3 
BRADYCARDIA 2  2  1 
 
                           Table -14b: Comparison of adverse effects 
 
Group  
              Nausea and vomiting 
Yes No 
 %  % 
Group C 3 11.5 23 88.5 
Group N 15 57.7 11 42.3 
Group P 14 53.8 12 46.2 
‗p‘ value between 
Groups 
C & N 
C & P 
N & P 
 
 
 
0.0238 – Significant 
                 0.046 – Significant 
       0.7822  - Not significant 
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Graph-7: Incidence of nausea and vomiting 
 
            
                 Incidence of nausea and vomiting was higher in Group- N and 
Group-P when compared with Group- C and this difference is statistically 
significant. There was no statistically significant difference in the incidence of 
nausea and vomiting among Group-P and Group-N. 
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DISCUSSION 
            Various drugs have been tried in the subarachnoid space along with local 
anaesthetics with the aim of improving the duration of post-operative analgesia. 
The cholinesterase inhibitor neostigmine is one among such adjuvants.  
  Even though neostigmine has shown to produce an increase in duration 
of analgesia, it was also associated with many unwanted side effects particularly 
nausea and vomiting, especially in higher doses. So to reduce the incidence of 
adverse effects and to prolong post operative analgesia other adjuvants have 
been used along with neostigmine. 
  The aim of this study was to systematically review the current evidence 
of analgesic enhancement of intrathecal neostigmine by the addition of 
transdermal nitroglycerine patch on bupivacaine spinal anaesthesia 
             Analgesic effect of intrathecally administered neostigmine is by release 
of acetylcholine in the spinal cord. Increased acetylcholine due to surgical 
stimuli and acetylcholine preserved from anticholinesterase activity of 
intrathecal neostigmine, binds to nicotinic and muscarinic nerve terminals in the 
spinal cord.  Studies have proved that cholinergic agonists produce inhibitory 
effects on spinal dorsal horn neurons, including spinothalamic tract .This 
suggest that a spinal cholinergic system plays an important inhibitory role in the 
modulation of pain pathways. 
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               Since NO was shown to be a CNS neurotransmitter, there has been 
reports of relationship between Nitric Oxide and pain processing in the CNS. It 
is accepted that Nitric Oxide may occupy an important position in the mediation 
of pain. Acetylcholine induces analgesia by activation of the arginine-Nitric 
Oxide-cGMP pathway. Enzyme Guanylate Cyclase activity in the CNS is 
markedly stimulated by Nitric Oxide generated from L-arginine or provided 
through transdermal NTG ,an exogenous source as in the present study. Nitric 
Oxide formation occurs during degradation of organic nitrates from transdermal 
NTG.   
              This study was designed to find out whether the analgesic effect of 
intrathecal neostigmine will be enhanced by transdermal NTG, which acts as an 
exogenous source of nitric oxide. In this study the duration of analgesia was 
analyzed as period from intrathecal drug administration till VAS score reaches 
4.  On statistical analysis, patient belonging to Group C complained of pain 
earlier than other groups, duration of analgesia being 2.5hours. There was 
statistically significant delay in the onset of pain in Group N and Group P. Our 
study showed a mean duration of 3.5 hours in patients belonging to Group N 
and 5.2 hours in patients belonging to Group P. 
              Lauretti, Gabriela R. et al. in 2000 conducted a study to determine 
whether association of transdermal nitroglycerine would enhance analgesia from 
a low dose of intrathecal neostigmine in patients undergoing gynaecologic 
surgery during spinal anaesthesia. They concluded that neither intrathecal 5 μg 
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neostigmine alone nor transdermal nitroglycerine alone (5 mg/day) delayed the 
time to administration of first rescue analgesics, but the combination of both 
provided an average of 550 min of effective postoperative analgesia after 
vaginoplasty. There was no significant difference in the incidence of adverse 
effects.. They suggested that transdermal nitroglycerine  and the central 
cholinergic agent neostigmine may enhance each other's antinociceptive effects 
which correlate with findings of my study. The increased incidence of adverse 
effects in my study may be due to usage of higher dose of neostigmine. 
              Gurvinder Kaur, Narjeet Osahan, Lalita Afzal in 2007 conducted a 
study to examine the effect of transdermal NTG patch (5mg/24hours) on 
intrathecally administered neostigmine (5μg)  along with 15mg bupivacaine and 
incidence of untoward effects. They found that average duration of analgesia in 
intrathecal neostigmine Group [Group I] was 6.5 hours and in neostigmine and 
transdermal nitroglycerine patch Group [Group II] was 9.10 hours. Duration of 
analgesia was significantly higher in patients in Group II as compared to Group 
I. The incidence of nausea was higher in Group I than in Group II. The 
enhancement of analgesia of intrathecal neostigmine by transdermal NTG in this 
study correlates with my study. The increased incidence of nausea and vomiting 
in my study may be due to usage of higher dose of neostigmine. 
            Fareed Ahmed.et. al. 2010 conducted a study to determine the effect of 
transdermal nitroglycerine patch on intrathecal neostigmine.  Patients were 
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allocated into four groups with Group I received 15 mg bupivacaine 
intrathecally,  Group II received 15mg of bupivacaine with 5μg neostigmine 
intrathecally, patients in Group III received 15mg of  bupivacaine with 1ml of 
normal saline intrathecally and transdermal NTG patch (5 mg/24 hours). 
Patients in Group-IV received 15 mg bupivacaine with 5µg of neostigmine 
intrathecally and transdermal NTG patch [5 mg/24 hours]. The mean duration of 
analgesia was 202.2min, 407.6min, 207.8 min and 581.6 min in Group [1] ,  
Group [II],  Group [III] , Group [IV] respectively. 
                 In my study intrathecal bupivacaine – transdermal nitroglycerine 
patch group was omitted since the above studies substantiated that transdermal 
nitroglycerine patch do not show analgesic potential of its own.  The 
enhancement of analgesia by intrathecal neostigmine and potentiation of 
analgesic effect of intrathecal neostigmine by transdermal NTG patch correlates 
with the findings of my study. No change in perioperative hemodynamic 
parameters which was observed in this study also correlates with my study. The 
increased incidence of nausea and vomiting in my study may be due to usage of 
higher dose of neostigmine. 
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CONCLUSION 
  On the basis of this study the following conclusions were drawn:- 
1) Spinal anaesthesia with 3ml 0.5% bupivacaine provided 2.5±0.26hrs of 
analgesia. 
 
2) Addition of intrathecal 25µg neostigmine to bupivacaine spinal 
anaesthesia significantly prolonged the duration of analgesia 
[3.52±0.38hrs].  
 
3) Addition of transdermal nitroglycerine patch [5mg/24hrs] and intrathecal 
25µg neostigmine to bupivacaine spinal anaesthesia provided the longest 
duration of analgesia [5.27±0.8 hrs]. 
 
4) Addition of intrathecal neostigmine and transdermal nitroglycerine patch 
to bupivacaine spinal anaesthesia did not produce any significant change 
in hemodynamic parameters 
 
5) Addition of intrathecal 25µg neostigmine to bupivacaine spinal 
anaesthesia significantly increased the incidence of nausea and vomiting. 
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PROFORMA 
A STUDY OF EFFICACY OF TRANSDERMAL NITROGLYCERINE PATCH IN   
ENHANCING ANALGESIA OF INTRATHECAL NEOSTIGMINE FOLLOWING 
HYSTERECTOMIES UNDER BUPIVACAINE SPINAL ANAESTHESIA      
NAME:                       IP-no:    DATE: 
AGE/SEX:              WEIGHT:   UNIT: 
DIAGNOSIS:              GROUP             PROCEDURE: 
PREOPERATIVE EXAMINATION                             INVESTIGATIONS  
                  
 
 
 
 
ASA GRADE 
SPINAL ANAESTHESIA 
TIME OF INTRATHECAL DRUG INJECTION: 
DRUG/DOSE 
POSITION 
SPACE 
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INTRA OPERATIVE MONITORING: 
Time PR MAP Sp02 Adverse effects Drugs 
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                                  RESULTS 
 
1.DURATION OF SURGERY: 
 
2.POST OPERATIVE BP and PR: 
TIME MAP PR 
 
VAS   score 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
. 
3.HEMODYNAMIC PARAMETERS: 
 MEAN BP MEAN PULSE RATE 
PRE OPERATIVE   
INTRA OPERATIVE   
POST OPERATIVE   
 
4.DURATION OF ANALGESIA: 
 
5.ADVERSE EFFECTS: 
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              MASTER CHART- Group-C       
NO: IP NO AGE WEIGHT Duration of                   PR                             MAP                 Adverse  duration of 
        surgery   Pre op intra op post op   pre op intra op post op effects Analgesia 
1 214191 55 45 120   98 97.7 93.3   96.5 94.2 98.2 nausea 140 
2 214209 45 70 110   88 84.8 86.2   98.2 94.6 94.2 nil 135 
3 211957 43 48 130   100 97.4 95.6   83.3 76.6 79.9 NIL 150 
4 214119 40 51 90   97 96.6 96.9   88.6 80.2 83.3 NIL 170 
5 210827 48 49 80   94 93.3 92.3   93.4 90.6 92.4 nil 160 
6 215925 38 45 100   76 66.8 68.9   90.6 86.6 88.8 bradycardia 170 
7 212791 50 48 110   72 68.6 72.3   96.6 93.6 96.8 NIL 170 
8 216112 47 54 90   96.6 98.8 98.3   96.6 90.4 95.6 NIL 120 
9 209928 38 56 75   89 83.3 87.3   86.2 82.3 86.9 NIL 130 
10 210820 42 58 60   115 112.5 110.6   77.9 74.5 73.3 hypotension 150 
11 215165 55 54 55   110 102.3 98.7   90.6 84.6 97.6 NIL 130 
12 203456 54 49 100   94 96.9 98.9   87.6 85.9 88.2 VOMITING 170 
13 198287 46 56 90   88 89.4 90.4   93.2 89.5 92.1 nil 150 
14 213498 55 60 80   95 94.3 98.3   87.6 84.3 82.3 nil 160 
15 213498 42 54 95   82.3 79.4 82.3   86.6 82.3 84.3 nil 150 
16 215912 49 47 90   79 84.3 87.6   91.2 87.8 89.1 nil 140 
17 200149 55 52 95   76 70.6 78.5   84.4 80.2 83.3 nausea 180 
18 199610 52 47 65   80.2 86.3 80.4   92.1 89.4 90.6 nil 140 
19 200314 50 55 70   96.6 100.4 95.5   86.5 76.5 82.3 hypotension 130 
20 245198 49 59 75   93.3 90.3 95.5   88.5 84.4 83.3 nil 160 
21 215819 55 46 85   99.9 95.4 100.2   95.5 92.3 95.5 nil 130 
22 200139 58 54 100   91.3 85.6 90.9   87.7 83.3 88.8 hypotension 145 
23 206781 47 52 95   88.3 90.3 92.3   86.5 83.8 85.5 nil 160 
24 204156 50 46 100   100 106.8 105.1   95.6 90.6 93.3 nil 160 
25 213418 52 62 110   85.6 89.3 90.4   87.6 85.3 88.9 nil 160 
26 201892 50 59 75   80.3 83.3 85.6   80.4 84.4 87.7 nil 150 
ix 
 
              MASTER  CHART   GROUP-N         
  AGE IP NO WEIGHT DURATION   MEAN PR                     MAP duration adverse  
        OF SURGERY   PREOP INTRA OP POST OP   PRE OP 
INTRA 
OP POST OP of analgesia effects 
1 48 210833 50 60   94 84.4 81.6   88 74.4 77.6 210 hypotension 
2 40 200822 46 65   118 112.8 116.8   103 94.4 91.9 200 vomiting 
3 45 214913 56 75   93 90.4 88.2   92.3 90.3 91.6 180 NIL 
4 48 197674 52 90   90 82.2 88.1   93.3 84.4 91.6 180 vomiting 
5 35 207380 60 80   120 110.6 109   92.3 91.3 92.6 240 nausea 
6 38 202416 48 60   94 87.6 95   92.3 83.3 83.6 190 NIL 
7 45 207927 50 70   98 88.3 83.3   95 82.2 86.6 180 vomiting 
8 40 210692 58 90   86 83.3 83.3   98 89.9 93.3 220 NIL 
9 50 208782 53 70   96 94.4 96.6   92 82.6 83.3 230 nausea 
10 40 209920 47 60   77 72.3 85.2   77 70.3 78.9 230 hypotension 
11 45 212136 60 75   74 73.3 73   90 89.2 87.2 180 nausea 
12 33 209921 48 75   80 76.6 73.3   85.9 85.2 83.2 180 NIL 
13 45 219845 45 60   110 108.6 112.6   92.2 87.3 85.6 210 nausea 
14 52 212390 49 90   84 83.2 84.6   89.4 86.4 83.9 210 NIL 
15 50 211100 56 120   82 78.4 78.3   92.6 89.4 87.3 220 vomiting 
16 48 205130 55 90   82 79.4 75.4   84.6 82.7 78.6 220 nausea 
17 47 198479 55 80   80 76.4 78.3   90.6 86.5 88.3 185 NIL 
18 47 205146 49 100   93 90.6 93.3   93.6 89.3 88.2 230 nausea 
19 53 207941 53 80   86 79.3 81.6   91.3 87.3 86.4 180 NIL 
20 55 198908 56 90   90 84.6 83.3   96.6 94.6 96.9 250 nil 
21 45 207836 56 110   86 82.5 82.7   92 89.6 86 220 NIL 
22 40 200819 48 75   94 87.5 86.6   80.7 80.6 88.3 220 nausea 
23 35 207099 46 110   96 88.5 88.3   86.3 82.3 83.6 240 NIL 
24 50 209739 49 120   74 73.4 72.4   89.3 85.4 86.6 220 bradycardia 
25 45 206147 54 100   90 86.4 90.2   89.3 84.6 89.9 230 nausea 
26 55 208280 60 85   93 92.2 92.6   89.3 86.3 88.5 240 NIL 
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      MASTER CHART    GROUP  P         
NO: 
  
AGE WEIGHT 
Duration of                           
            
PR     MAP     Adverse   Duration of 
IP NO Surgery   Pre op intra op post op   pre op intra op post op effects analgesia 
1 208058 45 52 65   83.2 79.4 81.6   90.6 81.5 85.6 nausea 330 
2 209516 45 54 72   102.6 104.8 104.6   93 82 89 nausea 370 
3 211074 39 56 75   94.5 98.8 93.9   96 93 92.3 NIL 370 
4 208665 38 55 75   98.4 98 110   79 76 71.1 nausea 280 
5 203233 40 45 70   115.4 116 112   80 79 78.8 NIL 400 
6 209797 40 49 75   79.5 76 75.00   80 78 77 NIL 340 
7 204376 47 52 60   104.8 91.8 96   98.3 82.3 87.4 nausea 310 
8 205494 36 53 70   79.6 77.4 78   80 75.6 77.2 NIL 330 
9 203834 42 50 80   92.3 86.8 85   87.5 86.6 84 nausea 300 
10 204831 43 46 70   89.7 89.8 92   76.6 67.8 75.5  hypotension 270 
11 207923 40 40 60   90.5 83.4 85   84 79.5 81.3 NIL 300 
12 202426 39 66 70   74.9 70.3 72.4   96.6 87.3 94.3 NIL 320 
13 197664 60 55 105   64.1 61.6 60.3   86 82.3 82.9 vomiting bradycardia 380 
14 193782 47 56 100   76.5 69.4 70.2   88 84.3 84.2 NIL 340 
15 206156 40 50 75   78.9 79 76   96 94.6 94.4 NIL 380 
16 210813 50 55 110   90.7 81.8 80.6   94.7 88.9 91.7 vomting 330 
17 200707 54 45 110   75.6 76.4 77.3   92 90.8 91.8 nausea 350 
18 206524 50 59 120   94.3 90.6 94.3   89.2 84.6 87.6 vomiting 200 
19 207606 53 45 70   96.1 89.4 95   100.7 92.3 96.8 NIL 270 
20 206181 35 50 75   88.5 94.6 95   84.6 78 83.3 nausea, hypotension 290 
21 209216 50 45 110   85.9 86.4 87   91.7 90.4 90.4 NIL 330 
22 205494 45 45 90   112.2 104.7 94.8   82.3 80.3 81.3 NIL 320 
23 205168 60 54 90   86.4 85.5 79   87.2 84.3 85.5 vomiting 290 
24 205163 55 60 100   72.4 65 70.6   96.2 92.3 93.6 nausea, bradycardia 300 
25 197812 55 54 105   108.9 92.4 82.3   90.7 79.6 87.7 NIL 205 
26 203274 50 54 110   82.3 83.9 78   81.3 73.3 79.4 vomiting 320 
 
 
